Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and chronic inflammation of airways and lung parenchyma. Our aim was to assess two important elements of intracellular signaling involved in regulation of inflammation in COPD in patients subjected to long-acting beta2-agonist or long-acting beta2-agonist plus long-acting antimuscarinic: peroxisome proliferator-activated receptor gamma (PPARγ) protein, which has antiinflammatory and immunomodulatory properties and cAMP response element binding protein (CREB) and activated (CREB-P) protein which has histone acetyltransferase activity and increases histone acetylation and transcriptional activation of chromatin. Twenty one stable COPD patients (18 males and 3 females, mean age 65 years) receiving 12 μg B.I.D formoterol were assayed before and after 3 month add-on therapy, consisting of 18 μg Q.D. tiotropium. In all patients, sputum induction, spirometry, lung volumes, and DLCO were performed before and after therapy. Sputum cells were isolated and processed to isolate cytosolic and nuclear fractions. PPARγ, CREB, or CREB-P proteins were quantified in subcellular fractions using Western blot. Tiotropium add-on therapy improved respiratory parameters: FEV1 and lung volumes. After therapy mean expression of PPARγ in cell nuclei was significantly increased by about 180%, while CREB and phosphorylated CREB levels in cytosol and nuclei were decreased by about 30%. Our data show that the mechanism whereby tiotropium reduces exacerbations may be associated not only with persistent increase in airway functions and reduced hyperinflation mediated by muscarinic receptors, but also with possible anti-inflammatory effects of the drug, involving increased PPARγ and decreased CREB signaling.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Belvisi, M. G., & Mitchell, J. A. (2009). Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. British Journal of Pharmacology, 158, 994–1003.
Casarosa, P., Kiechle, T., Sieger, P., Pieper, M., & Gantner, F. (2010). The constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergics. Journal of Pharmacology and Experimental Therapeutics, 333, 201–209.
Fogli, S., Pellegrini, S., Adinolfi, B., Mariotti, V., Melissari, E., Betti, L., Fabbrini, L., Giannaccini, G., Lucacchini, A., Bardelli, C., Stefanelli, F., Brunelleschi, S., & Breschi, M. C. (2011). Rosiglitazone reverses salbutamol-induced β(2)-adrenoceptor tolerance in airway smooth muscle. British Journal of Pharmacology, 162, 378–391.
Global Strategy for the Diagnosis, Management and Prevention of COPD. (2008). Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://www.goldcopd.org
Gosens, R., Zaagsma, J., Meurs, H., & Halayko, A. J. (2006). Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respiratory Research, 7, 73–88.
Grabiec, A. M., Tak, P. P., & Reedquist, K. A. (2008). Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: Should we keep our HATs on? Arthritis Research and Therapy, 10, 226.
Holownia, A., Mroz, R. M., Noparlik, J., Chyczewska, E., & Braszko, J. J. (2008). Expression of CREB-binding protein and peroxisome proliferator-activated receptor gamma during formoterol or formoterol and corticosteroid therapy of chronic obstructive pulmonary disease. Journal of Physiology and Pharmacology, 59(Suppl. 6), 303–309.
Holownia, A., Mroz, R. M., Skopinski, T., Kielek, A., Kolodziejczyk, A., Chyczewska, E., & Braszko, J. J. (2010). Tiotropium increases cytosolic muscarinic M3 receptors and acetylated H3 histone proteins in induced sputum cells of COPD patients. European Journal of Medical Research, 15(Suppl. 2), 64–67.
Kato, M., Komamura, K., & Kitakaze, M. (2006). Tiotropium, a novel muscarinic M3 receptor antagonist, improved symptoms of chronic obstructive pulmonary disease complicated by chronic heart failure. Circulation Journal, 70, 1658–1660.
Kaur, M., Holden, N. S., Wilson, S. M., Sukkar, M. B., Chung, K. F., Barnes, P. J., Newton, R., & Giembycz, M. A. (2008). Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: A role for protein kinase A. American Journal of Physiology. Lung Cellular and Molecular Physiology, 295, 505–514.
Khan, S. N., & Khan, A. U. (2010). Role of histone acetylation in cell physiology and diseases: An update. Clinica Chimica Acta, 411, 1401–1411.
Lim, E. J., Lu, T. X., Blanchard, C., & Rothenberg, M. E. (2011). Epigenetic regulation of the IL-13-induced human eotaxin-3 gene by CREB-binding protein-mediated histone 3 acetylation. Journal of Biological Chemistry, 286, 13193–13204.
Loh, L. C., Kanabar, V., D’Amato, M., Barnes, N. C., & O’Connor, B. J. (2005). Sputum induction in corticosteroid-dependant asthmatics: Risks and airway cellular profile. Asian Pacific Journal of Allergy and Immunology, 23, 189–196.
Meyer, T., Reitmeir, P., Brand, P., Herpich, C., Sommerer, K., Schulze, A., Scheuch, G., & Newman, S. (2011). Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD. Respiratory Medicine, 105, 900–906.
Miard, S., & Fajas, L. (2005). Atypical transcriptional regulators and cofactors of PPARγ. International Journal of Obesity, 29, 10–12.
Miller, M. D., & Marty, M. A. (2010). Impact of environmental chemicals on lung development. Environmental Health Perspectives, 118, 1155–1164.
Mroz, R. M., Holownia, A., Chyczewska, E., Drost, E. M., Braszko, J. J., Noparlik, J., Donaldson, K., & Macnee, W. (2007). Cytoplasm-nuclear trafficking of CREB and CREB phosphorylation at Ser133 during therapy of chronic obstructive pulmonary disease. Journal of Physiology and Pharmacology, 58, 437–444.
Ohta, S., Oda, N., Yokoe, T., Tanaka, A., Yamamoto, Y., Watanabe, Y., Minoguchi, K., Ohnishi, T., Hirose, T., Nagase, H., Ohta, K., & Adachi, M. (2010). Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clinical and Experimental Allergy, 40, 1266–1275.
Richards, D. B., Bareille, P., Lindo, E. L., Quinn, D., & Farrow, S. N. (2010). Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: A randomised controlled trial. Respiratory Medicine, 104, 668–674.
Viegi, G., Pistelli, F., Sherrill, D. L., Maio, S., Baldacci, S., & Carrozzi, L. (2007). Definition, epidemiology and natural history of COPD. European Respiratory Journal, 30, 993–1013.
Wollin, L., & Pieper, M. P. (2010). Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulmonary Pharmacology & Therapeutics, 23, 345–354.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Conflicts of interest: The authors declare no conflicts of interest in relation to this article.
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
Holownia, A., Mroz, R.M., Skopinski, T., Kolodziejczyk, A., Chyczewska, E., Braszko, J.J. (2013). Tiotropium Increases PPARγ and Decreases CREB in Cells Isolated from Induced Sputum of COPD Patients. In: Pokorski, M. (eds) Respiratory Regulation - The Molecular Approach. Advances in Experimental Medicine and Biology, vol 756. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4549-0_2
Download citation
DOI: https://doi.org/10.1007/978-94-007-4549-0_2
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4548-3
Online ISBN: 978-94-007-4549-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)